Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$23MCash on Hand
CF+ Cash Runway
Follow LFCR by emailGet an email when LFCR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LFCR, unsubscribe in one click. Privacy
📣 What LFCR Says Is Next
Q4 2026 · “Next Steps: Business as Usual While we are announcing this transaction today, it is subject to customary closing conditions and the receipt of stockholder approval and transaction-related regulatory approval, and it is expected to close at the end of Q4 2026.”
Company press release, Sep 28, 2026 · SEC filing
fourth quarter 2026 · “Additional Transaction Details The transaction is expected to close at the end of the fourth quarter 2026, subject to the approval of Lifecore’s stockholders, the receipt of required regulatory approvals, and the satisfaction of certain other closing conditions.”
Company press release, Sep 28, 2026 · SEC filing
in 2029 · “Drive margin improvement through operational and cost-containment initiatives 2024 – 2026 2027 – 2028 2029 + On track to achieve ~12% revenue CAGR and >25% Adjusted EBITDA margins in 2029 12 Aggressive and Achievable Growth Strategy”
Company press release, May 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Deal Proxy for a special meeting on December 23, 2026 to vote on adopting a merger agreement with Lifecore Inc. and Hazel Merger Sub, affiliates of Webster Equity Partners. Holders would receive $6.28 per share in cash plus one contingent value right per share. Form DEFM14A · SEC filing
Nov 5, 2026 ·
Deal HSR waiting period for the proposed merger with Lifecore Inc. expired early effective November 4, 2026, satisfying one closing condition. Completion still requires stockholder adoption of the merger agreement at a special meeting and other approvals. Form 8-K · SEC filing
Nov 4, 2026 ·
Earnings Lifecore Biomedical reported Q3 2026 revenue of $25.3 million, down 18.6% from $31.1 million, and a net loss of $40.1 million or $1.08 per diluted share. Nine-month revenue was $82.7 million, down 21.8%, with about $38.0 million in liquidity at quarter end. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 20, 2026 ·
Shareholder vote Lifecore Biomedical set November 4, 2026 as the record date for a special stockholder meeting to vote on adopting the September 27, 2026 merger agreement with Lifecore Inc. and Hazel Merger Sub, Inc. Form 8-K · SEC filing
Sep 29, 2026 ·
Deal Lifecore's subsidiary signed Amendment No. 3 with Alcon Research, effective November 1, 2026, extending the contract manufacturing agreement's initial term to December 31, 2034, with automatic 24-month renewals. Form 8-K · SEC filing
Sep 28, 2026 ·
Deal Lifecore agreed to be acquired by Webster Equity Partners affiliates for $6.28 per share in cash plus one non-tradable CVR per share, with CVRs worth up to $160 million in aggregate. Closing is expected at the end of Q4 2026 and includes a 30-day go-shop. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
LFCR holds $23M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure:0 · Low
No operating cash burn in latest filings
Recent financing filings on SEC EDGAR:
Sep 23, 2025 · Shelf registration, up to $150M · S-3
Share count 37,905,846 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full LFCR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LFCR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.